In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK options Nabi's nicotine addiction vaccine NicVAX; terminated

Executive Summary

After teaming up earlier this year, GlaxoSmithKline Biologicals SA and Nabi Biopharmaceuticals (vaccines) have decided to partner again--now Nabi has granted GSK an option to exclusively license worldwide its Phase III smoking cessation candidate NicVAX as well as any variations on the vaccine's presentation, dosage, or administration. GSK has also received exclusive global rights to next-generation nicotine addiction vaccines (the companies are also calling these the "future candidates") incorporating both GSK's technology and Nabi's IP.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies